Application of cell division protein FtsZ targeted inhibitor A3 in preparation of drug-resistant bacterium resisting drugs
Compound A3, a FtsZ targeted inhibitor, effectively inhibits drug-resistant bacteria and enhances methicillin sensitivity, addressing the challenge of drug-resistant bacteria by targeting the FtsZ protein for antibacterial drug development.
Patent Information
- Application Number
- CN202411228313.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-03
AI Technical Summary
The increasing prevalence of drug-resistant bacteria, such as MRSA and VRE, poses a significant challenge in clinical medication, and there is a lack of effective antibacterial molecules targeting the FtsZ protein for inhibiting bacterial division and proliferation.
Development of a FtsZ targeted inhibitor, compound A3, which inhibits the growth and division of drug-resistant bacteria including MRSA, VRE, and other strains by interfering with the FtsZ protein.
Compound A3 demonstrates a significant inhibitory effect on various drug-resistant bacteria, particularly MRSA and VRE, and enhances the sensitivity of methicillin against MRSA, offering a promising solution for developing new antibacterial drugs.
Smart Images

Figure CN119055653A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to application of a cell division protein FtsZ targeted inhibitor in the preparation of drugs against drug-resistant bacteria. Background Art
[0002] Bacterial infections are mainly treated with antibiotics in clinical practice. With the widespread use of antibiotics, bacterial resistance is becoming increasingly serious. For example, the emergence of methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Staphylococcus aureus (MDRSA), vancomycin-resistant enterococci (VRE), extended-spectrum β-lactamases (ESBLs) and NDM-1 (New Delhi metallo-β-lactamase 1) positive strains has brought great trouble to clinical medication. Some resistant strains are even out of drug use. Another worrying issue is the relatively lagging development of new antimicrobial drugs.
[0003] Recent studies have shown that FtsZ (filamenting temperature-sensitive protein Z) is an indispensable protein in the process of bacterial division. It plays a vital role in the process of bacterial division and proliferation. It exists in almost all bacteria and is highly conserved in morphology and not prone to mutation. When its biological activity is disturbed, the growth and reproduction of bacteria will be inhibited [2]. Therefore, the study of antibacterial molecules targeting FtsZ has important reference value for the development of a new generation of antibacterial drugs. At present, there is no report that 4-(4-methylpiperazine-1-yl)phenylvinyl-quinoline derivatives have the ability to target FtsZ protein, induce bacterial division, and thus exert antibacterial activity. Summary of the invention
[0004] In view of the above problems, the purpose of the present invention is to provide an application of a cell division protein FtsZ targeted inhibitor A3 in the preparation of anti-resistant bacteria drugs. The present invention provides an FtsZ targeted inhibitor A3, which has a significant inhibitory effect on a variety of drug-resistant bacteria and has important practical significance for the research and development of anti-resistant bacteria drugs.
[0005] The specific scheme adopted by the present invention is:
[0006] In the first aspect, a bacterial fission protein FtsZ targeted inhibitor is provided, wherein the inhibitor is compound A3, named (1-methyl-2-((Z)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-4-((E)-4-(4-methylpiperazin-1-yl)phenylvinyl)quinoline-1-iodide, with a molecular formula of C 32 H 33 IN 4S, the structural formula is shown in formula (I):
[0007] In a second aspect, the above inhibitors are used in any of the following: (1) in vitro antibacterial activity; (2) preparation of drugs for treating drug-resistant bacteria.
[0008] A third aspect provides an antibacterial drug comprising the above-mentioned inhibitor.
[0009] The antibacterial drugs are drugs against Staphylococcus aureus, Escherichia coli, Enterococcus and Bacillus subtilis.
[0010] The Staphylococcus aureus is methicillin-resistant Staphylococcus aureus.
[0011] The Escherichia coli is drug-resistant Escherichia coli.
[0012] The enterococci are vancomycin-resistant enterococci.
[0013] The antibacterial drug also contains pharmaceutically acceptable excipients or other compatible drugs.
[0014] The pharmaceutically acceptable excipients are pharmaceutical excipients, including solvents, disintegrants, flavoring agents, preservatives, colorants or adhesives.
[0015] The dosage form of the antibacterial drug is injection, tablet, pill, capsule, suspension or emulsion.
[0016] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0017] (1) The targeted FtsZ protein inhibitor A3 of the present invention has a significant inhibitory effect on a variety of drug-resistant bacteria, especially on vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus;
[0018] (2) The targeted FtsZ protein inhibitor A3 of the present invention can significantly increase the sensitivity of methicillin to methicillin-resistant Staphylococcus aureus. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is a graph showing the effects of the blank control (Figure A) and the FtsZ protein inhibitor A3 (Figure B) on the growth morphology of Bacillus subtilis in Example 3 (40×).
[0020] Figure 2 This is a graph showing the effect of the FtsZ protein inhibitor A3 on the dynamic aggregation of the FtsZ protein in Example 4. DETAILED DESCRIPTION
[0021] The present invention provides an FtsZ protein inhibitor, which is a compound A3 (1-methyl-2-((Z)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-4-((E)-4-(4-methylpiperazin-1-yl)styryl)quinolin-1-ium iodide), and its molecular formula is C 32 H 33 IN 4 S, the structural formula is shown in formula (I):
[0022] The above-mentioned targeted FtsZ protein inhibitor A3 can be used to prepare antibacterial drugs.
[0023] The antibacterial drug is a drug against Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus.
[0024] The antibacterial drug is a drug against Escherichia coli, including drug-resistant Escherichia coli.
[0025] The antibacterial drug is an anti-enterococcal drug, including vancomycin-resistant enterococci.
[0026] The antibacterial drug is a drug against Bacillus subtilis.
[0027] The antibacterial drug is a drug that can increase the sensitivity of methicillin to methicillin-resistant Staphylococcus aureus.
[0028] The antibacterial drug also contains pharmaceutically acceptable excipients or other compatible drugs.
[0029] The pharmaceutically acceptable excipients mentioned above refer to conventional pharmaceutical excipients, such as solvents, disintegrants, flavoring agents, preservatives, colorants and adhesives.
[0030] The dosage form of the anti-drug-resistant bacteria drug is preferably an injection, tablet, pill, capsule, suspension or emulsion.
[0031] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.
[0032] Example 1 Test of antimicrobial activity
[0033] In this example, the minimum inhibitory concentration (MIC) (μg / mL) value of the FtsZ protein inhibitor A3 was determined using the broth microdilution method. The minimum inhibitory concentration (MIC) of the test compound was determined according to the broth microdilution procedure described in the Clinical and Laboratory Standards Institute (CLSI) guidelines.
[0034] The implementation steps are as follows:
[0035] (1) Preparation of culture medium and antimicrobial drug stock solution: The prepared MH broth culture medium was sterilized by autoclaving at 121°C for 30 min and then cooled; the test compound was dissolved in DMSO to prepare a 38.4 mg / mL stock solution, which was sterilized by filtration using a 0.22 μm filter membrane for later use.
[0036] (2) Activation and expansion of test bacteria: Spread the frozen test bacteria on TSB agar plates and activate and culture at 37°C for 24 h; inoculate a single colony obtained from the activation culture into 5 mL of TSB medium and culture at 37°C with shaking overnight.
[0037] (3) Seed plate: The OD value was measured at a wavelength of 600 nm using an ELISA reader to calculate the bacterial concentration. The bacterial solution was then diluted with MH broth to a concentration of approximately 5 × 10 5 CFU / mL, add blank culture medium to the outermost well of the 96-well plate, and add 100 μL of bacterial solution to each of the remaining wells for later use.
[0038] (4) Adding drugs: The blank culture medium at the outermost edge of the 96-well plate was used as a blank control. 96 μL of bacterial solution was added to each well of the second column, and then 4 μL of the compound stock solution prepared in step 1 was added. After fully mixing, 100 μL of the mixed solution was pipetted and added to the third column. After fully mixing again, 100 μL of the mixed solution was pipetted and added to the fourth column. When the process was repeated to the 11th column, 100 μL of the mixed solution was pipetted and discarded. That is, the drug was added by the half-dilution method. Finally, the drug concentrations in each well of the second to 11th columns were 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, 2 μg / mL, 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, and 0.125 μg / mL, respectively. DMSO was used as a solvent control, and ampicillin (AMP), vancomycin (VAN), methicillin (MET), and rifampicin (RIF) were used as positive controls.
[0039] (5) Incubation: Place the 96-well plate in a 37°C constant temperature incubator and incubate for 24 h.
[0040] (6) Result judgment: The blank control wells showed no obvious bacterial growth and were clear. The lowest drug concentration at which the wells were completely clear was taken as the MIC value, i.e., clarity visible to the naked eye indicated 90% inhibition of bacterial growth.
[0041] (7) Test bacteria: The bacteria used in the microbroth dilution method include Staphylococcus aureus ATCC29213, methicillin-resistant Staphylococcus aureus ATCC BAA-41, methicillin-resistant Staphylococcus aureus ATCC 43300, multidrug-resistant Staphylococcus aureus ATCC BAA-44, vancomycin-resistant Staphylococcus aureus VISA, Staphylococcus epidermidis ATCC 12228, methicillin-resistant Staphylococcus epidermidis MRSE, Bacillus subtilis 168, Escherichia coli ATCC 25922, multidrug-resistant Escherichia coli BAA-2469, Enterococcus faecium ATCC 49624, and vancomycin-resistant Enterococcus faecium ATCC 700221.
[0042] (8) The test results are shown in Table 1. The test compounds can inhibit the reproduction of multiple drug-resistant bacteria in vitro and can be used to prepare antibiotic drugs against drug-resistant bacteria.
[0043] Table 1 MIC values of the tested compounds against the tested bacteria (μg / mL)
[0044] Example 2 FtsZ protein inhibitor A3 increases the sensitivity of methicillin to methicillin-resistant Staphylococcus aureus (MRSA)
[0045] The implementation steps are as follows:
[0046] (1) The combination of the compound and methicillin against methicillin-resistant Staphylococcus aureus (MRSA) was tested using the checkerboard assay, based on the determination of the compound and methicillin MICs.
[0047] (2) Methicillin was prepared into a 50 mg / mL stock solution using DMSO, and filtered for sterilization.
[0048] (3) Recovery and expansion culture: refer to the minimum inhibitory concentration (MIC) experiment.
[0049] (4) The distribution of drug concentrations is shown in Table 2 below (the values outside the brackets are compound MIC multiples, and the values inside the brackets are methicillin MIC multiples).
[0050] Table 2 Distribution of drug concentration 1 / 32(1) 1 / 32(1 / 2) 1 / 32(1 / 4) 1 / 32(1 / 8) 1 / 32(1 / 16) 1 / 32(1 / 32) 1 / 16(1) 1 / 16(1 / 2) 1 / 16(1 / 4) 1 / 16(1 / 8) 1 / 16(1 / 16) 1 / 16(1 / 32) 1 / 8(1) 1 / 8(1 / 2) 1 / 8(1 / 4) 1 / 8(1 / 8) 1 / 8(1 / 16) 1 / 8(1 / 32) 1 / 4(1) 1 / 4(1 / 2) 1 / 4(1 / 4) 1 / 4(1 / 8) 1 / 4(1 / 16) 1 / 4(1 / 32) 1 / 2(1) 1 / 2(1 / 2) 1 / 2(1 / 4) 1 / 2(1 / 8) 1 / 2(1 / 16) 1 / 2(1 / 32) 1(1) 1(1 / 2) 1(1 / 4) 1(1 / 8) 1(1 / 16) 1(1 / 32)
[0051] (5) According to the chessboard layout in Table 2 above, dilute the bacterial solution to 10 6CFU / mL, take the diluted bacterial solution from the dosing tank to prepare bacterial solution containing 6 gradient concentration compounds, and inoculate 100μL per well as shown in the table. Then add 4μL of methicillin stock solution to the first column and perform half-dilution according to the minimum inhibitory concentration. After the seed plate dosing is completed, the 96-well plate is placed in a 37℃ constant temperature incubator for 24h.
[0052] (6) Result judgment: The blank control wells were clear without bacterial growth. The lowest drug concentration that made the wells completely clear was the MIC value of FtsZ protein inhibitor A3 and methicillin (MET) when used in combination. That is, visible clarity with the naked eye inhibited 90% bacterial growth. The fractional inhibitory concentration (FIC) formula was: FIC = MIC in combination / MIC alone; fractional inhibitory concentration index (FICI) = FIC A3 +FIC MET .
[0053] Table 3 Synergistic effect of FtsZ protein inhibitor A3 and methicillin (MET) on MRSA
[0054] The FIC index was less than 0.5, indicating that A3 could improve the sensitivity of methicillin to methicillin-resistant Staphylococcus aureus (MRSA), and the two had a synergistic effect.
[0055] Example 3 Bacterial morphology study
[0056] In this example, an Olympus IX71 inverted fluorescence microscope was used to observe the growth morphology of Bacillus subtilis under the action of the FtsZ protein inhibitor A3.
[0057] B. subtilis 168 was selected as the test bacteria; since the growth of bacteria was effectively inhibited when the compound concentration was the MIC value, the experimental concentration was 0.5×MIC to obtain a certain concentration of bacterial suspension for observation.
[0058] The implementation steps are as follows:
[0059] (1) Dilute the cultured bacterial suspension with sterilized MH broth to a concentration of about 5 × 10 5 CFU / mL.
[0060] (2) Add the diluted bacterial solution and the stock solution of compound A3 to a sterilized 5 mL centrifuge tube, and the total volume is set to 1 mL. The final concentration of the compound is 0.5×MIC value for inhibiting B. subtilis 168, i.e., 2 μg / mL. The solvent control group is the bacterial solution without drug treatment.
[0061] (3) Place the centrifuge tube in step (2) in a constant temperature shaker and incubate at 200 rpm and 37°C for 4 to 5 h until bacterial growth becomes turbid. Observe the bacterial morphology under a 40× lens.
[0062] (4) The experimental results are shown in the attached Figure 1 As shown, compared with the blank group and the solvent control group, the bacterial morphology of the drug-added group was significantly elongated, which preliminarily determined that the compound could act on the target FtsZ protein, causing the bacteria to elongate due to the inability to divide normally, and then die.
[0063] Example 4 FtsZ protein inhibitor A3 interferes with the dynamic polymerization of FtsZ protein
[0064] (1) The in vitro polymerization of FtsZ protein was measured using a multifunctional microplate reader with the wavelength set at 340 nm and the experimental temperature at 25°C.
[0065] (2) Add 50 mM MOPS buffer (pH 6.5) and FtsZ protein at a final concentration of 6 μM to a 96-well plate, and add compounds of a series of concentrations for incubation for 10 min, with 1% DMSO as a negative control. At the same time, set up a control well without FtsZ protein for background subtraction.
[0066] (3) Add 50 mM KCl, 2 mM MgCl 2 and 1 mM CaCl 2 Then continue scanning for 5 min.
[0067] (4) Add 1 mM GTP solution, continue scanning for 2000 s, and record A 340nm The scanning data were analyzed and processed, and all the scanning data were deducted from the corresponding background data.
[0068] (5) The experimental results are shown in the attached Figure 2 As shown, A3 can promote the dynamic aggregation of FtsZ protein in a concentration-dependent manner.
[0069] It should be noted that the above-described embodiments should be understood as illustrative rather than limiting the scope of protection of the present invention, and the scope of protection of the present invention shall be subject to the claims. For those skilled in the art, some non-essential improvements and adjustments made to the present invention still fall within the scope of protection of the present invention without departing from the essence and scope of the present invention.
Claims
1. A targeted inhibitor of bacterial fission protein FtsZ, the inhibitor is compound A3, named (1-methyl-2-((Z)-(3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-4-((E)-4-(4-methylpiperazin-1-yl)phenylvinyl)quinoline-1-iodide, with a molecular formula of C 32 H 33 IN4S, the structural formula is shown in formula (I):
2. Use of the bacterial fission protein FtsZ targeted inhibitor according to claim 1 in any of the following: (1) Antibacterial in vitro; (2) Preparation of drugs against drug-resistant bacteria.
3. A drug for combating drug-resistant bacteria, comprising the bacterial fission protein FtsZ targeted inhibitor according to claim 1.
4. The anti-drug resistant bacteria drug according to claim 3, characterized in that: The anti-drug-resistant bacteria drug is a drug against Staphylococcus aureus, Escherichia coli, enterococcus and Bacillus subtilis.
5. The anti-drug resistant bacteria drug according to claim 4, characterized in that: The Staphylococcus aureus is methicillin-resistant Staphylococcus aureus.
6. The anti-drug resistant bacteria drug according to claim 4, characterized in that: The Escherichia coli is drug-resistant Escherichia coli.
7. The anti-drug resistant bacteria drug according to claim 4, characterized in that: The enterococci are vancomycin-resistant enterococci.
8. The anti-drug resistant bacteria drug according to claim 4, characterized in that: The anti-drug-resistant bacteria drug also contains pharmaceutically acceptable excipients or other compatible drugs.
9. The anti-drug resistant bacteria drug according to claim 8, characterized in that: The pharmaceutically acceptable excipients are pharmaceutical excipients, including solvents, disintegrants, flavoring agents, preservatives, colorants or adhesives.
10. The anti-drug resistant bacteria drug according to claim 4, characterized in that: The dosage form of the antibacterial drug is injection, tablet, pill, capsule, suspension or emulsion.
Citation Information
Patent Citations
Application of indol-ethylene substituted quinoline derivative in preparing drug-resistance bacterium medicines
CN108309977A
Quinoline aroma ethylene derivative as well as preparation method and application thereof
CN109111397A
Application of styrene quinoline derivative to preparation of drug-resistance bacteria antagonizing medicine and drug-resistance bacteria antagonizing medicine
CN110302201A
Thiazole orange benzyl quaternary ammonium salt derivative as well as preparation method and application thereof
CN110526910A
Quinoline derivative as well as preparation method and application thereof
CN116143770A
